Thursday, March 31, 2022

FDA reputation takes another hit after scathing aducanumab advisory panel meeting

At a time when the FDA can little afford another reputation challenge, an advisory panel review for Biogen’s much-debated Alzheimer’s candidate turned out to be a debacle—and the fallout was immediate.

Scientists, researchers and analysts piled on the agency after the panel of outside experts first roasted the agency’s hype for aducanumab and then capped it off with a resounding “no” vote for approval.

The FDA’s image is already under a cloud after this year’s emergency authorizations of questionable COVID-19 treatments—under apparent political pressure. FDA Commissioner Stephen Hahn was forced to apologize for misrepresenting data on convalescent plasma at a presidential press conference. As if to redeem those mistakes, the agency took some quick steps to de-politicize vaccine development as the election loomed.

A hit to the FDA’s reputation isn’t just about the agency, either. It bleeds onto the pharma industry, too, as consumers take to social media to voice their worries about drugs FDA approves—and, crucially, question a COVID-19 vaccine even if stamped with the agency’s approval.

RELATED: FDA faces a reputation crisis amid Trump pressure for fast COVID action—and that’s bad news for pharma

Enter aducanumab, which has been controversial for years, and only came out of the Biogen dustbin after a follow-up analysis of one trial offered a glimmer of hope. Ahead of the meeting, the sliced-and-diced data itself came in for criticism from analysts and beyond.

The FDA put itself in the line of fire by publishing pre-meeting documents that seemed designed to push for a full-on approval, despite some less-than-flattering statistical analyses buried in the briefing packet.

“The applicant has provided substantial evidence of effectiveness to support approval,” the documents said up front, in a sentence that rang across social media when the documents were released.

During Friday’s meeting, the panelists excoriated FDA officials for teeing up aducanumab for a rubberstamp approval. In the end, they voted unanimously against backing the drug for approval, with one abstention.

Former FDA reviewer Erick Turner, M.D., called the AdComm “kabuki theater,” on Twitter, adding later that the “FDA is on a slippery slope. Later step could be to fire statisticians.”

Analysts quickly said the discussion and vote didn’t bode well for the Biogen drug—partly because the FDA simply can’t afford to give it a green light now.

“Approving aducanumab, in the face of such an overwhelmingly negative vote and commentary, is virtually impossible and would destroy the agency’s reputation at a very tenuous time for the regulator, ahead of potential actions on COVID vaccines,” Baird’s Brian Skorney wrote.

Bloomberg’s biotech and pharma columnist Max Nisen wrote the day before the AdComm about the public trust and image issue the FDA was courting.

RELATED: FDA panel slams Biogen’s controversial Alzheimer’s med

“The agency’s reputation eroded this year after ill-advised emergency authorizations of hydroxychloroquine and convalescent plasma to treat Covid-19,” he said. “As it attempts to rebuild trust ahead of the evaluation and rollout of a Covid-19 vaccine, it should demonstrate that there’s still a high bar instead of further tarnishing its image.”

Yet that’s exactly what may happen. It’s still possible the FDA could approve the drug; it generally follows panel recommendations but isn’t required to do so.

As SVB Leerink analysts wrote, “While we have never seen a drug get approved with such a negative panel, we also have never seen FDA briefing documents that were so blatantly obvious about the FDA’s positive view.”

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...